Myriad Genetics announced a collaboration with Flatiron Health. This collaboration allows physicians to order Myriad’s MyRisk Hereditary Cancer Test and view the results of the test directly in Flatiron’s cloud-based Electronic Medical Record, EMR, platform, OncoEMR. MyRisk is the first hereditary cancer test to be incorporated into Flatiron’s OncoEMR. The integration allows 4,200 providers at over 800 community-based cancer care locations across the U.S. in Flatiron’s network to conveniently order, receive, and review MyRisk testing results directly through their daily OncoEMR system.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics announces five research collaborations to study MRD testing
- Myriad Genetics and Ultima Genomics to explore UG 100 sequencing platform
- USPTO issues 3rd patent to Myriad aiding in bringing MRD assay to market
- Myriad Genetics initiated with an Equal Weight at Morgan Stanley
- Myriad Genetics to share new data on genetic testing advancements